Sugi Predict

Sugi Predict / Compounds / SCHEMBL4427290

SCHEMBL4427290

SCHEMBL4427290

Fc1ccc(C(Br)c2ccc(F)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 3/20 0.46
▸ TDO2 P48775 2/20 0.46
▸ HDAC3 O15379 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ HDAC10 Q969S8 1/20 0.39
▸ HDAC11 Q96DB2 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ HDAC9 Q9UKV0 1/20 0.39
▸ HDAC5 Q9UQL6 1/20 0.39
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7520122 0.89 LMNA (0.42) IDO1TDO2CYP19A1ALDH1A1LMNA
SCHEMBL11288745 0.87 TSHR (0.41) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL11642941 0.83 CHRNB2 (0.42) CYP19A1ALDH1A1
SCHEMBL10358705 0.83 GSK3B (0.42) CYP19A1ALDH1A1CES2CES1
SCHEMBL28553177 0.82 KDM4E (0.48) CA2CA9CYP19A1ALDH1A1LMNA
SCHEMBL2732165 0.81 IDO1 (0.46) IDO1TDO2HDAC3HDAC4HDAC1
SCHEMBL3105632 0.78 IDO1 (0.36) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL7129754 0.78 IDO1 (0.48) IDO1TDO2HDAC3HDAC4HDAC1
SCHEMBL16027483 0.77 IDO1 (0.42) IDO1TDO2HDAC3HDAC4HDAC1
SCHEMBL506690 0.77 IDO1 (0.42) IDO1TDO2HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115103841-B Substituted quinolinone piperazine compounds useful as T cell activators 百时美施贵宝公司 2024-12-27 — — CN disclosed
US-20240174631-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY RECOVERY THERAPEUTICS, INC. 2024-05-30 — — US disclosed
CN-112654621-B Substituted naphthyridinone compounds useful as T cell activators 百时美施贵宝公司 2024-05-14 — — CN disclosed
US-11866430-B2 Naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-09 — — US disclosed
EP-4291177-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY Recovery Therapeutics, Inc. (US) 2023-12-20 — — EP disclosed
EP-3814348-B9 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-11-01 — — EP disclosed
EP-3814348-B1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 — — EP disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed
US-4957927-A (Diarylmethoxy alkyl)-1-pyrrolidines and piperidines having cardiovascular activity LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) 1990-09-18 — — US disclosed
US-4766215-A Histamine H1 -receptor antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 1988-08-23 — — US disclosed
EP-0271192-A2 Purine histamine H1 antagonists, their preparation and pharmaceutical compositions containing them AMERICAN HOME PRODUCTS CORPORATION (US) 1988-06-15 — — EP disclosed
US-4716166-A PURINE DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 1987-12-29 — — US disclosed
EP-0090733-B1 DISUBSTITUTED POLYMETHYLENE IMINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ADIR (FR) 1985-10-30 — — EP disclosed
US-4514398-A Disubstituted polymethylene imines ADIR (FR) 1985-04-30 — — US disclosed
EP-0090733-A1 Disubstituted polymethylene imines, processes for their preparation and pharmaceutical compositions containing them ADIR (FR) 1983-10-05 — — EP disclosed
US-4377578-A ANTIANAPHYLACTIC AGENTS, ANTIHISTAMINES JANSSEN PHARMACEUTICA, N.V. (BE) 1983-03-22 — — US disclosed
US-4250176-A BENZIMIDAZOLE-2-ONE, BENZOTHIAZOL-2-ONE, OR BENZOXAZOL-2-ONE SUBSTITUTIONS, ANTIANAPHALACTIC AGENTS, ANTIHISTAMINES JANSSEN PHARMACEUTICA N.V. (BE) 1981-02-10 — — US disclosed
US-4200641-A ANTIANAPHYLACTIC AGENTS, ANTIHISTAMINES JANSSEN PHARMACEUTICA, N.V. (BE) 1980-04-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174631-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY FGF1, FGF2, FGFR1 IDO1 4370/4885TDO2 4615/4885HDAC3 287/4885
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG IDO1 1773/4885TDO2 3317/4885HDAC3 2226/4885
US-11866430-B2 Naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG IDO1 1965/4885TDO2 3543/4885HDAC3 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.